Inflammation Triggers Unsustainable Immune Response to Chronic Viral Infection
Scientists at the University of Basel discovered a fundamental new mechanism explaining the inadequate immune defense against chronic viral infection. These results may open up new avenues for vaccine development.
Under the influence of interferons, chronic viral infections cause strong inflammation. This causes the B cells to initiate an inadequate immune response which first optimizes the production of antibodies for a short period, but then rapidly subsides.
University of Basel
In the course of an infection or upon vaccination, specialized cells of our immune system, so-called B cells, produce antibodies that bind viruses and inactivate them. In the context of chronic viral infections such as HIV or hepatitis C virus, however, antibody production by B cells is quantitatively inadequate and starts too late.
A team of scientists headed by Prof. Daniel Pinschewer at the Department of Biomedicine, University of Basel, reports that the inadequate antibody response to chronic viral diseases is due to the strong inflammatory reaction upon infection. While most pronounced at the onset of an infection, inflammation can persist for decades, especially in HIV/AIDS.
Hasty immune response lasts only short-term
Under the influence of inflammatory messengers, so called interferons, B cells produce as many antibodies as they possibly can. Unfortunately, this hasty response occurs at the expense of sustainability. B cells that turn on antibody production too quickly lose their potential to proliferate and die shortly thereafter. As a consequence, the immune response takes an impetuous start but subsides rapidly.
The scientists assume that this panic reaction of B cells reflects a mechanism ensuring an optimized response to acute life threatening infections. In the context of chronic infections, however, the battle is not decided within a matter of days, but rather only after months or years. Under these circumstances, the hasty reaction of our body seems inappropriate and may actually favor the virus.
Cornerstone for new vaccines
For viral diseases such as HIV or hepatitis C protective vaccines remain unavailable. The scientists are hopeful that the discovery of this fundamental mechanism may provide a basis to improve vaccination strategies against chronic viral diseases.
Original publication
Fallet et al.; "Interferon-driven deletion of antiviral B cells at the onset of chronic infection"; Science Immunology; 2016
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
New biotech venture PHIOGEN to tackle the global threat of antimicrobial resistance - By optimizing nature’s defenders, the team has produced unprecedented phage treatments
Proxygen Announces Strategic Collaboration with Merck to Develop Molecular Glue Degraders
Rockeby awarded bird flu tests tender from Middle East
Rentschler focuses on biotechnology
How cancer genes become independent - Study sheds light on the mysterious evolution of DNA rings
Blueprint of Oxytocin Receptor Facilitates Development of New Autism Drugs
Merck and Pfizer Initiate Phase III Trial to Evaluate Avelumab as First-line Treatment for Ovarian Cancer
Provence Technologies and Neuroptis Biotech partner to develop a new compound for treating dry eye syndrome
Mayo researchers develop new laboratory cell lines to study treatment for ATC
Diabetes advance: Researchers find gene that causes resistance to insulin - Discovery is first gene known to affect how insulin works, not how it is produced
ZEISS Ventures invests in life science start-up InSphero to drive 3D cell culture research - Strategic investment is closely linked to ZEISS Research Microscopy Solutions and its capabilities in automated, high-resolution imaging and 3D image analysis
